Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Transnational Cannabis's earnings before interest and taxes (EBIT) for the
three
months ended in Nov. 2019 was $-18.59 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Nov. 2019 was $-101.26 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Transnational Cannabis's annualizedROC % for the quarter that ended in Nov. 2019 was -8.85%.
Transnational Cannabis's annualizedROC (Joel Greenblatt) % for the quarter that ended in Nov. 2019 was -2,205.55%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Transnational Cannabis's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transnational Cannabis EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Transnational Cannabis's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Transnational Cannabis's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Nov. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-101.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transnational Cannabis (TRCNF) has a EBIT of $-101.26 Mil as of Nov. 2019. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Transnational Cannabis.
Is Transnational Cannabis' EBIT too high?
Transnational Cannabis' current EBIT is $-101.26 Mil.
How does Transnational Cannabis' EBIT compare to CLSH and KAYS?
Transnational Cannabis' EBIT of $-101.26 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Transnational Cannabis. Transnational Cannabis's current EBIT is $-101.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transnational Cannabis stock overvalued right now?
Transnational Cannabis (TRCNF) has a current EBIT of $-101.26 Mil. The current EBIT is $-101.26 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Transnational Cannabis (TRCNF), the current EBIT is $-101.26 Mil as of Nov. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Transnational Cannabis Ltd, formerly ICC International Cannabis Corp is a Canadian company which is engaged in planning, designing, building and operating cannabis production, processing, and distribution facilities. The company through its holdings is engaged in the pharmaceutical distribution, wholesale importation, research, and development, as well as working interests in industrial hemp licenses in Greece, licenses to cultivate, produce, distribute, store, and export Cannabis and Cannabis derivatives in Colombia, the Kingdom of Lesotho, Africa, and Denmark.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRCNF has been successfully added to your 
